US Pharma MarketingAfter buying Apellis for $5.6B, Biogen is cutting most of its pipeline work
Biogen pauses or cancels most R&D programs from its $5.6B Apellis buyout and lays off staff, keeping its focus on Empaveli and Syfovre. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
Biogen has paused or canceled investment in the “majority” of research programs that came with its $5.6 billion acquisition of Apellis Pharmaceuticals and laid off “a small number” of employees from the biotech, a spokesperson ...
Source: Endpoints News